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Abstract 
Intracerebroventricular (ICV) administration of the hypothalamic neuropeptide 
neuromedin U (NMU) or the adipostat hormone leptin increases plasma ACTH and 
corticosterone.  The relationship between leptin and NMU in the regulation of the 
hypothalamo-pituitary adrenal (HPA) axis is currently unknown.  In this study, leptin 
(1nM) significantly increased the release of CRH from ex-vivo hypothalamic explants by 
207 ± 8.4% (p < 0.05 vs. basal), an effect blocked by the administration of anti-NMU 
immunoglobulin (IgG).  ICV administration of leptin (10μg, 0.625nmol) increased plasma 
ACTH and corticosterone 20 minutes post injection [(plasma ACTH (pg/ml): vehicle 63 ± 
20; leptin, 135 ± 36; p < 0.05) (plasma corticosterone (ng/ml): vehicle, 285 ± 39, leptin, 
452 ± 44; p < 0.01)].  These effects were partially attenuated by the prior administration of 
anti-NMU IgG.  Peripheral leptin also stimulated ACTH release, an effect attenuated by 
prior ICV administration of anti-NMU IgG.  We examined the diurnal pattern of 
hypothalamic NMU mRNA expression and peptide content, plasma leptin and plasma 
corticosterone.  The diurnal changes in hypothalamic NMU mRNA expression were 
positively correlated with hypothalamic NMU peptide content, plasma corticosterone and 
plasma leptin.  ICV administration of anti-NMU IgG significantly attenuated the dark 
phase rise in corticosterone [corticosterone (ng/ml), vehicle, 493 ± 38; NMU IgG, 342 ± 
47 (p < 0.05)].  These studies suggest that NMU may play a role in the regulation of the 
HPA axis and partially mediate leptin-induced HPA stimulation. 
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Introduction 
Activity of the hypothalamo-pituitary adrenal (HPA) axis is altered by obesity and caloric 
deprivation.  Leptin, the protein product of the Lep (obese) gene, is released into the 
circulation from adipose tissue and regulates food intake, energy expenditure and the HPA 
axis in part, via the hypothalamus (1-4).  Leptin influences hypothalamic neurons via the 
long variant isoform of the leptin receptor, Ob-Rb (1;5;6).  
 
The effects of leptin on the HPA axis are complex.  The Ob-Rb is abundant on 
corticotropin-releasing hormone (CRH) neurons in the parvocellular region of the 
paraventricular nucleus (PVN) (7).  It has been reported that administration of anti-CRH 
antibodies or the CRH receptor antagonist alpha-helical CRH(9-41) (α-hCRH(9-41)) inhibits 
the anorectic effects of leptin (8;9).  These authors suggest that leptin partially regulates 
energy balance via hypothalamic CRH. 
 
However, leptin has also been reported to have an inhibitory effect on the HPA axis.  
Leptin deficient (ob/ob) mice are hypercorticosteronemic (10).  Administration of leptin to 
fasted rodents (11), ob/ob mice (11) or immobilization-stressed rodents (12) inhibits 
plasma ACTH and corticosterone levels. In addition, CRH mRNA expression in the PVN 
is increased in fasted rats, which have low circulating levels of leptin and ob/ob mice, in 
which leptin is absent (11;12).  This apparent inverse relationship between plasma leptin 
and plasma corticosterone appears to support the hypothesis that leptin inhibits the HPA 
axis (11).  However, recent publications suggest that leptin can stimulate the HPA axis 
under certain circumstances.  Intracerebroventricular (ICV) administration of leptin has 
been shown to stimulate corticosterone secretion at the onset of the dark phase (13).  In 
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addition, a single ICV injection of leptin in the early light phase has shown to dose-
dependently increase plasma ACTH and corticosterone secretion (14).   ICV injection of 
leptin also increases the expression of CRH and its receptor, CRH-R2 in the PVN (15).  
Leptin may therefore have both inhibitory and stimulatory roles in the regulation of the 
HPA axis.  The mechanism by which leptin interacts with the HPA axis is currently 
unknown. 
 
Neuromedin U (NMU) is a gastrointestinal and central nervous system (CNS) peptide 
which has been reported to reduce food intake (16;17), activate the sympathetic nervous 
system (18) and increase energy expenditure (17;19).  These effects are similar to those 
observed following leptin administration (20-22).  NMU also potently stimulates the HPA 
axis and induces stress-related behaviors (16). Within the hypothalamus, NMU mRNA is 
predominately expressed in the arcuate, suprachiasmatic and dorsomedial nuclei (17;23), 
which also express the Ob-Rb (24). NMU immunoreactive fibers project to the PVN (25).  
ICV or intra-PVN administration of NMU to rats significantly increases plasma ACTH 
and corticosterone (16;26).  Incubation of ex-vivo hypothalamic explants with NMU 
significantly increases the release of CRH (16).  The effects of NMU on the HPA axis are 
thought to be mediated via the NMU 2 receptor (NMU2R) (16), which is expressed in the 
ependymal layer of the third ventricle, the PVN (17;19;23;27;28) and the arcuate nucleus 
(23).  
 
NMU mRNA expression in the arcuate nucleus is reduced following a 48 hour fast, when 
leptin concentrations are low, and reduced in ob/ob mice, where leptin is absent (17).  
Incubation of ex-vivo hypothalamic explants with leptin increases the release of NMU in 
 5
vitro (16).  However there is little other published data on the interaction between leptin 
and NMU systems with regards to regulation of the HPA axis. 
 
Here we investigate the hypothesis that hypothalamic NMU in part mediates the leptin-
induced activation of the HPA axis by using an anti-NMU immunoglobulin G (anti-NMU 
IgG) to block endogenous NMU signaling.  We have also used anti-NMU IgG to 
investigate the role of endogenous hypothalamic NMU in the normal diurnal rise in plasma 
corticosterone. 
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METHODS AND MATERIALS 
Animals    
Male Wistar rats (specific pathogen free; Charles River, Margate, UK), weighing 200-250 
g, were maintained in individual cages under controlled temperature (21-23 C) and light 
(12 h light/dark cycle, lights on at 0700 h) with ad libitum access to food (RM1 diet, SDS 
UK Ltd. Witham, UK), unless otherwise described.  Food intake and body weight were 
measured daily throughout the study and all rats were handled daily to habituate and 
minimize any stress.  All animal experimentation was conducted in accordance with 
accepted standards of humane animal care and carried out under the 1986 British Animals 
(Scientific Procedures) Act, License number 70/5516. 
 
Materials    
Recombinant murine leptin was a gift from M. Chiesi and N. Levens of Novartis (Basel, 
Switzerland).  Reagents for the ex-vivo hypothalamic explant experiments were supplied by 
BDH (Poole, Dorset, UK).  All peptides were reconstituted at the beginning of each study 
in vehicle (non-immune rabbit serum (NIRS)). 
 
Antibody purification  
The anti-NMU IgG was produced and purified using methods previously described 
(29;30). 
 
Intracerebroventricular (ICV) cannulation and injection 
Animal surgical procedures and handling were carried out as previously described (30). 
All compounds were injected using a 27 gauge stainless steel injector placed in and 
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projecting 1mm below the tip of the cannula.  Cannula placement was confirmed by a 
positive dipsogenic response to angiotensin II (150ng).  Only those animals showing a 
positive dipsogenic response were included in the data analysis (>98%).  All animals were 
habituated to the injection process by a subsequent saline injection.   
 
Leptin and immunoblockade of leptin by anti-NMU IgG on hypothalamic CRH 
release 
A static incubation system was used as described previously (16).  Briefly, ad libitum fed 
male Wistar rats were killed by decapitation and the whole brain immediately removed. 
The brain was mounted with the ventral surface uppermost and placed on a vibrating 
microtome (Microfield Scientific Limited, Dartmouth, UK).  A 1.7mm slice was taken 
from the basal hypothalamus and blocked lateral to the Circle of Willis.  The hypothalamic 
slices were incubated in individual chambers containing 1ml artificial cerebrospinal fluid 
(aCSF), (20mM NaHCO3, 126mM NaCl, 0.09mM Na2HPO4, 6mM KCl, 1.4mM CaCl2, 
0.09mM MgSO4, 5mM glucose, 0.18mg/ml ascorbic acid and 100µg/ml aprotinin (Bayer, 
Haywards Heath, UK)) equilibrated with 95% O2 and 5% CO2. 
 
The tubes were placed on a platform in a water bath maintained at 37 C. After an initial 2 
hour equilibration period, the hypothalami were incubated for 45 minutes in 600µl aCSF 
(basal period), before being challenged with leptin (1, 10 and 100nM), 1nM leptin 
combined with anti-NMU IgG (1:20), anti-NMU IgG alone (1:20) or NIRS (1:20) in 600μl 
aCSF for 45 minutes.  The viability of the tissue was verified by 45 minutes of exposure to 
aCSF containing 56mM KCl. Isotonicity was maintained by substituting K+ for Na+. 
Hypothalamic explants that failed to show peptide release above that of basal in response 
to hyperkalaemic aCSF were excluded from the data analysis (<10%).  The experiment 
 8
was repeated twice, with eight to twelve hypothalamic slices given each treatment. At the 
end of each period, aCSF was collected and stored at –20 C until measurement of CRH by 
RIA.  To confirm whether the effect of anti-NMU IgG was specific for leptin, ex vivo 
hypothalamic explants were incubated in either 1000nM ghrelin combined with anti-NMU 
IgG or 1000nM ghrelin with NIRS.  This dose of ghrelin has previously been shown to 
stimulate CRH release (31). 
 
Anti-NMU IgG immunoblockade on the effects of ICV leptin on the HPA axis  
Ad libitum fed male Wistar rats received a single ICV injection, between 0900 and 1000 
h, of either vehicle, leptin (10µg, 0.625nmol) alone, anti-NMU IgG (5μl, concentration 
150mg/ml) alone or leptin (0.625nmol) and anti-NMU IgG (5μl) together.  The same 
dose of anti-NMU IgG has previously been shown to block the inhibitory actions on food 
intake of 1nmol NMU administered ICV (30).  Morimoto et al reported that ICV 
administration of leptin significantly increased plasma ACTH and corticosterone 20 
minutes post-injection (14).  Rats were therefore killed by decapitation 20 minutes post-
injection (n = 10-15 / group / time point) and trunk blood was collected into plastic 
lithium heparin tubes containing 0.6mg aprotinin and plastic tubes containing potassium 
EDTA (final concentration of 1.2-2 mg EDTA/ml blood).  Plasma was separated by 
centrifugation, frozen and stored at –20 C for the measurement of ACTH and 
corticosterone by immunoradiometric assay (IRMA) and RIA respectively, according to 
the manufacturer’s protocol.   
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Anti-NMU IgG immunoblockade on the effects of peripheral leptin on the HPA axis 
Ad libitum fed male Wistar rats received a single ICV injection, between 0900 and 1000 
h, of either vehicle or anti-NMU IgG (1μl).  Five minutes post injection, animals 
received an i.p. injection of either leptin (1.1mg/kg) or saline.  Animals were killed by 
decapitation 20 minutes post ICV injection (n = 10/group) and trunk blood was collected 
into plastic lithium heparin tubes containing 0.6mg aprotinin and plastic tubes containing 
potassium EDTA (final concentration of 1.2-2mg EDTA/ml blood).  Plasma was 
separated by centrifugation, frozen and stored at -20 C prior to the measurement of 
ACTH and corticosterone by IRMA and RIA respectively. 
 
Diurnal changes in hypothalamic NMU mRNA expression and peptide content, 
plasma leptin and corticosterone levels. 
Ad libitum fed male Wistar rats were decapitated at the following time points 0700 h 
(lights on), 1100 h, 1500 h, 1700 h, 1900 h, (lights off), 2100 h, 2300 h, 0300 h, and 0700 
h) (n = 15 / per time point). At each time point hypothalami were dissected out and snap 
frozen in liquid nitrogen. 
 
For quantification of hypothalamic NMU mRNA expression, hypothalamic mRNA was 
extracted (n = 10 / time point) using Tri-Reagent (Helena Biosciences, Sunderland, UK) 
according to the manufacturer’s protocol. Quantification of NMU mRNA expression was 
performed as previously described (32) using the Ambion RNase protection assay (RPA) 
III kit (Ambion Inc., TX) under conditions optimized within our laboratory. The NMU 
riboprobe corresponded to nucleotides 121 to 336 of the full length rat NMU sequence 
(Accession number NM_022239), a 215bp product.  Briefly, 5µg RNA was hybridized 
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overnight at 42 C with 1.3 x 103 Bq 32P[CTP] labeled riboprobe. Rat ß-actin was used as 
an internal control (Ambion).  Reaction mixtures were digested with RNase A/T1, the 
protected fragments precipitated and separated on a 4% polyacrylamide gel. The dried 
gel was exposed to a phosphorimager screen overnight and bands quantified by image 
densitometry using ImageQuant software (Molecular Dynamics, Sunnyvale, CA). 
For quantification of hypothalamic NMU peptide content, peptide was extracted from 
hypothalami by boiling in 0.5M acetic acid (10ml/g hypothalamus) for 20 minutes (n = 5/ 
time point).  The hypothalamic extracts were cooled on ice and then stored at –20 C until 
determination of NMU peptide content by RIA.  To normalize the data, the hypothalamic 
protein content was determined using the Coomassie PlusTM Protein Assay Kit (Pierce 
Biotechnology Inc., Rockford, IL).    
Trunk blood was collected into plastic lithium heparin tubes containing 0.6mg aprotinin, 
separated by centrifugation, frozen and stored at -20 C until measurement of plasma leptin 
and corticosterone by RIA according to the manufacturer’s protocol.  
 
The effect of peripheral leptin on hypothalamic NMU mRNA and peptide 
expression 
Ad libitum fed male Wistar rats received a single i.p. injection, between 0900 and 1000 h 
of either saline or leptin (1.1mg/kg).  This dose of leptin has previously been shown to 
activate hypothalamic neurons (33;34).  Four hours post injection, animals were 
decapitated, brains removed and the hypothalamus dissected out and snap frozen in 
liquid nitrogen.  Hypothalamic mRNA was extracted as previously described and 
hypothalamic NMU mRNA expression was quantified by RPA.  To measure 
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hypothalamic NMU peptide content, peptide was extracted as described above and 
hypothalamic NMU content was quantified by RIA.  
 
The effect of intracerebroventricular administration of anti-NMU IgG on the 
nocturnal rise of corticosterone 
Hypothalamic NMU peptide content rose between 1900 and 2100 h (Figure 3A) 
therefore ad libitum fed male Wistar rats received a single ICV injection of either vehicle 
or anti-NMU IgG (5μl) just prior to the onset of the dark phase (1830 h) (n = 10-15 / 
group / time point) to block the rise in hypothalamic NMU peptide.  Plasma 
corticosterone levels begin to rise from 1500 h (Figure 3B) and peak at 2100 h.  In order 
to examine the blockade of endogenous NMU during the nocturnal rise in corticosterone, 
animals were decapitated at 1930 h.  Trunk blood was collected into plastic lithium 
heparin tubes containing 0.6mg aprotinin.  Plasma was separated by centrifugation, 
frozen and stored at –20 C until measurement of corticosterone by RIA according to 
manufacturer’s protocol.   
 
Radioimmunoassays (RIA) 
CRH-immunoreactivity (IR) and NMU-IR were measured using established assays (16). 
The intra- and inter-assay variations of both assays were less that 10%.  Plasma 
corticosterone (MP Biomedicals, Hampshire, UK) and leptin (Linco Research Inc., St. 
Louis, MO) levels were measured using commercially available RIA kits. The intra- and 
inter-assay coefficients of variation for plasma corticosterone were less than 10%.  Plasma 
ACTH (IDS Ltd, Tyne and Wear, UK) was measured by IRMA. The intra- and inter-assay 
coefficients of variation for ACTH were less than 4%.   
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Statistical analysis 
Data are presented as mean ± sem. Data from ex-vivo hypothalamic explant release 
experiments were compared by paired t- test between the basal period and the test period.  
For the ICV studies, groups were compared by one-way ANOVA followed by a post-hoc 
Fisher’s least significant difference test (Systat, Evanson, IL).  Correlation between 
hypothalamic NMU mRNA and peptide expression, plasma corticosterone and leptin 
levels with respect to time was determined by Spearman Rank Order Correlation.  In all 
cases p < 0.05 was considered statistically significant.  
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Results  
Leptin and immunoblockade by anti-NMU IgG on hypothalamic CRH release 
Incubation of ex-vivo hypothalamic explants with 1, 10 and 100nM leptin significantly 
increased CRH immunoreactivity (IR) [CRH-IR (percentage of basal ± sem) basal, 100 ± 
11; leptin (1nM) 219 ± 20 (p < 0.05 vs. basal); leptin (10nM) 270 ± 19 (p < 0.01 vs. basal); 
leptin (100nM) 207 ± 18 (p < 0.01 vs. basal) n = 8-12 / treatment] (Figure 1A).  The 
increase in CRH release (Figure 1A) from hypothalamic explants following incubation of 
leptin (1nM) was attenuated by anti-NMU IgG (1:20) [CRH-IR (percentage of basal ± 
sem)  basal, 100 ± 7.7; leptin (1nM), 207 ± 8.4 (p < 0.05 vs. basal); leptin (1nM)/anti-
NMU IgG, 116 ± 23 (p = n.s. vs. basal; p < 0.05 vs. leptin); anti-NMU IgG 92 ± 6.9 (p = 
n.s. vs. basal, p < 0.05 vs. leptin), NIRS 109  ± 7.4 (p = n.s. vs. basal; p < 0.05 vs. leptin) n 
= 8-12 / treatment] (Figure 1B).  The effect of leptin on CRH release was not affected by 
incubation with NIRS (CRH-IR (percentage of basal ± sem) basal, 100 ± 18.5; leptin 
(1nM)/NIRS 167.4 ± 8.5 (p < 0.05 vs. basal).  To confirm the specificity of the effect for 
leptin, hypothalamic explants were incubated with 1000nM ghrelin and either NIRS or 
anti-NMU IgG.  Ghrelin stimulated CRH release, an effect which remained in the presence 
of anti-NMU IgG (data not shown). 
 
Anti-NMU IgG immunoblockade on the effect of ICV leptin on the HPA axis 
ICV administration of leptin significantly increased plasma ACTH and corticosterone at 20 
minutes post-injection when compared to the vehicle injected group [plasma ACTH 
(pg/ml): vehicle, 73 ± 25; leptin (0.625nmol), 135 ± 36; p < 0.05 vs. vehicle; plasma 
corticosterone (ng/ml): vehicle, 284 ± 39; leptin (0.625nmol), 452 ± 44; p < 0.01 vs. 
vehicle) n = 10-15 / group] (Figure 2A and B).  The leptin-induced increase in plasma 
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ACTH and corticosterone was attenuated by the administration of anti-NMU IgG [plasma 
ACTH (pg/ml): leptin / anti-NMU IgG, 43 ± 11; p = n.s. vs. vehicle; p < 0.01 vs. leptin; 
plasma corticosterone (ng/ml): leptin / anti-NMU IgG, 319 ± 44; p = n.s. vs. vehicle, p < 
0.01 vs. leptin)] (Figure 2A and B).  Anti-NMU IgG alone had no effect on plasma ACTH 
or corticosterone [plasma ACTH (pg/ml): anti-NMU IgG, 74 ± 27; plasma corticosterone 
(ng/ml): anti-NMU IgG, 312 ± 38] (Figure 2A and B). 
 
Anti-NMU IgG immunoblockade on the effect of peripheral leptin on the HPA axis. 
Intraperitoneal administration of leptin significantly increased plasma ACTH at 20 minutes 
post injection when compared to the vehicle injected control group. The leptin induced 
increase in plasma ACTH was attenuated by ICV administration of anti-NMU IgG.  Anti-
NMU IgG alone had no effect on plasma ACTH [plasma ACTH (pg/ml) saline / vehicle, 
86.4 ± 12.2; leptin / vehicle, 135.6 ± 24.4; saline / anti-NMU IgG, 59.8 ± 7.0, leptin / anti-
NMU IgG 66.8 ± 13.7 p<0.05 leptin / vehicle vs. saline / vehicle, saline / anti NMU IgG 
and leptin / anti-NMU IgG, n = 10 / group] (Figure 2C).  Intraperitoneal injection of leptin 
caused a non-significant increase in plasma corticosterone 20 minutes post injection when 
compared to the vehicle injected control group.  There was a slight attenuation of this 
effect by ICV administration of anti-NMU IgG although again, this was not significant 
[plasma corticosterone (ng/ml) saline / vehicle, 279.3 ± 36.6; leptin / vehicle 387.6 ± 53.2; 
saline / anti-NMU IgG 242.4 ± 46.0; leptin / anti-NMU IgG 296.1 ± 45.2 n = 10 / group].   
 
Diurnal changes in hypothalamic NMU mRNA expression and peptide content, 
plasma corticosterone and plasma leptin. 
Hypothalamic NMU mRNA expression showed a diurnal rhythm with levels peaking at 
2300 h, 4 hours after lights off (Figure 3A).  Hypothalamic NMU peptide content 
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displayed a diurnal variation reaching a nadir at 1100 h, 4 hours after lights on.  NMU 
peptide content subsequently increased throughout the day peaking at the onset of the dark 
phase (1900 h) (Figure 3B).  Hypothalamic NMU mRNA expression was positively 
correlated with NMU peptide content (r2 = 0.514, p < 0.02).   
 
As expected, plasma corticosterone displayed a diurnal variation, with levels rising 
towards the end of the light phase (1700 h) and peaking at 2100 h (Figure 3A).  A similar 
diurnal pattern existed between plasma corticosterone and hypothalamic NMU peptide. 
However, this correlation did not achieve statistical significance (r2 = 0.303, p = 0.062). 
 
Plasma leptin exhibited a diurnal pattern, reaching a nadir at 1100 h, 4 hours after lights 
on.  Plasma leptin began to rise at the onset of the dark phase (1900 h) and peaked at 2100 
h (Figure 3C).  Plasma leptin levels were positively correlated with hypothalamic NMU 
mRNA expression (r2 = 0.321, p < 0.05) and peptide content (r2 = 0.588, p < 0.01) (see 
Supplemental figures for regression plots).   
 
The effect of peripheral leptin on hypothalamic NMU mRNA and peptide 
expression. 
A single i.p. injection of leptin had no effect on hypothalamic NMU mRNA expression 
(saline, 24.9 ± 1.2 arbitrary units; 1.1mg/kg leptin, 22.4 ± 1.2 n = 10) or NMU peptide 
content (saline, 5.6 ± 0.5 fmol/μg protein; 1.1mg/kg leptin, 4.9 ± 0.4 fmol/μg protein n = 
10) 4 hours post injection.   
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ICV administration of anti-NMU IgG on the nocturnal rise of plasma corticosterone 
Blocking endogenous hypothalamic NMU signaling with an ICV injection of anti-NMU 
IgG at the onset of the dark phase attenuated the nocturnal rise in plasma corticosterone at 
1930 h [plasma corticosterone (ng/ml): vehicle, 493 ±  36; anti-NMU IgG, 342 ± 48 (p < 
0.05 vs. vehicle) n = 10 -15 / group] (Figure 4).  
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Discussion 
The evidence for the role of leptin in the regulation of the HPA axis is conflicting.  Models 
of leptin deficiency suggest leptin inhibits the HPA axis (11;35) and leptin administration 
has been reported to suppress HPA axis activity (12;36).  However, there is also evidence 
that leptin can stimulate the HPA axis (13-15).  These current studies suggest that leptin 
stimulates the release of CRH from ex-vivo hypothalamic explants.  This is in accord with 
studies showing that leptin increases CRH release, peptide concentration and mRNA 
expression in the PVN (14;37).  In our current experiments, ICV administration of leptin 
increased plasma ACTH and corticosterone 20 minutes post injection, in agreement with 
published data (14). Leptin therefore appears to stimulate the HPA axis via the release of 
CRH under these specific conditions.  A number of hypothalamic circuits are thought to 
regulate different aspects of “stress” and HPA axis activation. It is therefore quite possible 
that leptin can play both stimulatory and inhibitory roles in the regulation of the 
neuroendocrine response to stress. For example, both neuropeptide Y (NPY) and CRH 
neurons are leptin responsive, although leptin inhibits NPY release whilst stimulating CRH 
(1).  Both of these neuropeptides stimulate the HPA axis but may be differentially 
regulated by different types of stress (13). 
 
Hypothalamic release of NMU from ex-vivo hypothalamic explants is stimulated by leptin 
(16) and hypothalamic NMU mRNA expression is reduced in models of low or absent 
circulating leptin (17).  NMU increases the release of CRH from ex-vivo hypothalamic 
explants (16) while intra-PVN administration of NMU increases plasma ACTH and 
corticosterone (16).  The increase in plasma ACTH and corticosterone following ICV 
administration of NMU is attenuated in CRH-deficient mice and in rodents pre-treated 
with α-hCRH(9-41) (38;39).  Though it is currently unknown if NMU2R is co-expressed 
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with CRH neurons, NMU2R is expressed in the PVN (17;27;40) and ICV administration 
of NMU increases c-fos, a marker of neuronal activation, in CRH neurons in the PVN 
(41;42).  The authors of these reports have suggested that the stimulatory effect of NMU 
on the HPA axis is mediated via CRH. 
 
A number of leptin-responsive neuropeptides have been shown to regulate the HPA axis, 
including NPY (43).  Our data suggest that the actions of leptin on the HPA axis may be 
partially mediated by the NMU/CRH pathway.   Co-administration of anti-NMU IgG with 
leptin blocks leptin-induced CRH release from ex-vivo hypothalamic explants.  
Furthermore, ICV administration of anti-NMU IgG partially attenuates the leptin-induced 
increase in plasma ACTH and corticosterone in vivo following ICV administration.  Leptin 
is produced by adipose tissue, circulates and enters the hypothalamus via the blood brain 
barrier.  The effect of peripheral administration of leptin on the HPA axis is therefore 
perhaps more relevant than ICV administration.  Peripheral administration of leptin caused 
a significant increase in plasma ACTH at 20 minutes post-injection.  This effect is 
attenuated by ICV pre-treatment with anti-NMU IgG.  These results suggest that NMU 
may mediate some of the effects of leptin on the HPA axis via CRH.  The arcuate nucleus 
is incompletely isolated by the blood brain barrier and is thus in direct communication 
with peripheral signals from the blood and the CSF (44).  It is therefore possible that 
arcuate NMU neurons respond to circulating leptin, signaling to CRH neurons in the PVN 
leading to activation of the HPA axis. 
 
Our results suggest that both hypothalamic NMU peptide content and mRNA expression 
vary diurnally in rhythms that correlate with the diurnal variation in plasma leptin and 
 19
corticosterone.  Furthermore, ICV administration of anti-NMU IgG partly attenuated the 
normal night-time rise in plasma corticosterone suggesting that NMU may play a role in 
regulating the diurnal changes in plasma corticosterone. Whilst indicating hypothalamic 
NMU mRNA expression and peptide content at specific time points, the diurnal patterns 
do not give an indication of the dynamics of peptide synthesis and release.  For example, it 
is unclear whether high levels of hypothalamic NMU peptide content indicate increased 
peptide release or replenishment of neuronal peptide levels following release.  The 
hypothalamus expresses low levels of NMU making it difficult to carry out a detailed 
dynamic investigation.  In this current study, samples were only taken every 4 hours.  
More frequent sampling is required to determine the exact temporal relationship between 
hypothalamic NMU mRNA expression and peptide content, plasma corticosterone and 
plasma leptin.  It is possible that NMU may not mediate the initial rise in corticosterone 
but may be involved in the maintenance of high corticosterone levels at the beginning of 
the dark phase.   
 
The hypothalamic pathways that control the HPA axis are complex and are not fully 
characterized.  The results presented in this manuscript suggest that leptin may mediate a 
stimulatory action on the HPA axis by altering hypothalamic NMU expression and release.     
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Figure 1:  Leptin-induced CRH release is attenuated by administration of anti-NMU 
IgG.  CRH release from ex-vivo hypothalamic explants (n = 8–12/treatment) after a 45 min 
basal incubation period followed by (A) 45 min exposure to 1, 10, 100 nM leptin in aCSF 
and (B) 45 min exposure to 1 nM leptin, leptin (1 nM) / anti-NMU IgG (1:20) in aCSF, 
anti-NMU IgG (1:20) in aCSF and non-immune rabbit serum (NIRS) (1:20) in aCSF.  
Data expressed as a percentage of basal ± sem. Significant values are indicated *p < 0.05 
vs. basal; **p < 0.01 vs. basal; # p < 0.05 leptin / NMU IgG vs. NMU IgG and NIRS. 
 
Figure 2: The stimulatory effects of leptin on the HPA axis are blocked by ICV 
administration of anti-NMU IgG.  Plasma ACTH (A) and corticosterone (B) 20 minutes 
post injection of ICV vehicle, leptin (0.625nmol) or anti-NMU IgG (5µl) (n = 10- 12 
/group).  Plasma ACTH (C) 20 minutes post ICV injection of either anti-NMU IgG (5µl) 
or vehicle and peripheral administration of either leptin (1.1mg/kg) or saline. Plasma 
ACTH: a, p < 0.05 vs. vehicle; b, p < 0.05 vs. leptin /anti- NMU IgG; c, p < 0.05 vs. anti-
NMU IgG.  Plasma corticosterone: a, p< 0.01 vs. vehicle, b, p < 0.05 vs. leptin / anti-NMU 
IgG; c, p < 0.05 vs. anti-NMU IgG. 
 
Figure 3: Diurnal patterns of hypothalamic NMU peptide content, plasma 
corticosterone and plasma letpin.   Diurnal profiles of  (A) hypothalamic NMU mRNA 
expression, (B) hypothalamic NMU peptide content, (C) plasma corticosterone and (D) 
plasma leptin at nine time points 0700, 1100, 1500, 1700, 1900 (lights out), 2100, 2300, 
0300, 0700 h (n = 10 / time point).  Open bar indicates light phase and black bar indicates 
dark phase.   
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Figure 4: Immunoblockade of hypothalamic NMU attenuates the nocturnal rise in 
corticosterone.  Ad libitum fed male Wistar rats received an injection of either anti-NMU 
IgG (5µl) or vehicle in the early dark phase. Plasma corticosterone was measured at 1930 h 
(n = 10-12). Significance values as indicated * p < 0.05 vs. vehicle 
 22
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